SynteractHCR, GOG sign 3-year agreement to leverage services

By Melissa Fassbender contact

- Last updated on GMT

SynteractHCR is a full-service, international contract research organization. (Image: iStock/Jirsak)
SynteractHCR is a full-service, international contract research organization. (Image: iStock/Jirsak)

Related tags: Contract research organization, Clinical trial, Pharmaceutical industry

The international contract research organization (CRO) and non-profit organization have signed a three-year “teaming agreement” to advance clinical trials for gynecologic malignancies.

The GOG Foundation, Inc. (GOG) works with biopharmaceutical drug developers researching therapies in gynecologic cancer indications and features a network of more than 300 investigational institutions in Japan, Korea, Australia, and the US.

As part of the agreement, GOG will recommend SynteractHCR as its preferred CRO to assist its clients with their clinical trial needs.

Conversely, SynteractHCR will recommend GOG to its current and potential customers – providing sponsors access to the non-profit’s network in order to accelerate investigator selection and patient recruitment.

Wendel Barr, CEO of SynteractHCR told us the agreement with GOG combines the companies experience in drug development in oncology and gynecology.

In aligning with GOG, we are collaborating with an organization with the same dedicated focus to bringing treatments forward in areas of greatest need, and doing so in a more targeted, precise and efficient fashion to benefit our sponsors​,” Barr added.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars